ArticleKidney international reports2017

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

Flavio Vincenti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.